1Q Revenues: $17.8 billion (+2%)
1Q Earnings: $4.4 billion (-1%)
Comments: Domestic sales increased 0.6%. International sales increased 2.8%, reflecting operational growth of 3.6% and a negative currency impact of 0.8%. Worldwide Pharmaceutical sales were $8.2 billion, up 1%. REMICADE sales were down 6% to $1.7 billion, offset by growth drivers in new products including DARZALEX, with sales of $255 million. IMBRUVICA sales were $409 million, up 57%. STELARA sales were $823 million, up 12%. INVEGA SUSTENNA/XEPLION/TRINZA sales were up 18% to $604 million. During the quarter, the company announced a definitive agreement to acquire Actelion Ltd., a biopharmaceutical company, for approximately $30 billion.